Plain-English translation of NCT06809140 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two medications called and to treat muscle-invasive bladder cancer. The study aims to shrink tumors without removing the bladder in patients who respond well to the treatment. If the cancer completely goes away after the initial treatment, you would continue on maintenance therapy for several more months.
Traditionally, muscle-invasive bladder cancer has been treated by surgically removing the entire bladder, which significantly impacts quality of life. This trial is exploring whether this new combination of medications can eliminate the cancer effectively enough to avoid surgery in some patients.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions of both medications every three weeks for three cycles (about 9 weeks). After that, you would undergo imaging, urine tests, and a cystoscopy procedure to see if the cancer has completely disappeared. If it has, you would continue treatment for 14 more cycles: one medication for the first six cycles and the other medication for all 14 cycles. If cancer remains, you would proceed to bladder removal surgery instead.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States